The prize recognizes foundational discoveries about regulatory T cells and the FOXP3 gene that redefined immune tolerance and opened avenues to treat autoimmune disease, enable transplantation, and advance immuno-oncology. ISB celebrates Dr. Brunkow’s leadership and collaborative science.
The pioneering work of Mary Brunkow and Fred Ramsdell began with a mysterious mutant mouse known as “scurfy,” leading them to identify the FOXP3 gene and unlock how regulatory T cells prevent autoimmune disease — discoveries that now point to new treatments in cancer and autoimmunity.
Co-Author Craig Mundie and ISB’s Dr. Jim Heath discuss AI’s rapid evolution, ethical considerations, and potential to revolutionize science and society in a compelling Town Hall event.
A team of researchers has developed a powerful new tool that could transform how doctors treat multiple myeloma, a complex and often unpredictable blood cancer.
Sui Huang challenges the prevailing view of cancer as purely genetic in a new essay published in PLOS Biology. Huang and colleagues suggest non-genetic factors and disrupted gene regulatory networks may play crucial roles in cancer development.
ISB researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.
ISB’s Gibbons Lab developed a breakthrough method that analyzes food-derived DNA in fecal metagenomes, allowing for data-driven diet tracking without the need for burdensome questionnaires.